Patent · US Active

Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression

US11578329B2 · kind B2 · utility

0Cited by

1References

30Claims

0Family size

Assignees

Novo Nordisk A/S · DK
Dicerna Pharmaceuticals, Inc. · US

Inventors

Utsav SAXENA · Watertown, US
Henryk T. Dudek · Wellesley, US
Natalie Wayne Pursell · Westborough, US
Nicole Alexis Spiegelman · Somerville, US
Markus Robert Latta · Avedøre Landsby, DK
Birgitte Andersen · Avenue Madeleine, DK

Key dates

Filing date	Apr 19, 2022
Grant date	Feb 14, 2023
Priority date	—
Expiry date	Apr 19, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/533
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.